By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DelMar Pharmaceuticals 

999 West Broadway
Suite 720
  British Columbia  V5Z 1K5  Canada
Phone: 1-604-629-5989 Fax:



Company News
DelMar Pharmaceuticals Announces Financing Update And Initial Subscriptions Of $2.0 Million In Registered Direct Offering 7/28/2015 10:36:45 AM
DelMar Pharmaceuticals Expands GBM Clinical Trial With Fifth Clinical Trial Site Added In Denver, Colorado 7/20/2015 9:10:39 AM
DelMar Pharmaceuticals To Present Updated Phase I/II Clinical Data On Val-083 In The Treatment Of Refractory Glioblastoma Multiforme At GBM2015: 2nd International Symposium On Clinical And Basic Investigation In Glioblastoma 7/9/2015 9:50:18 AM
BIO2015 EXCLUSIVE: DelMar Pharmaceuticals Files for $8M Fund Raise, BioSpace (DHX) Learns 6/17/2015 12:13:51 PM
DelMar Pharmaceuticals Invited To Present At The World NSCLC Summit On June 23-24, 2015 6/15/2015 8:09:21 AM
BIO2015: DelMar Pharmaceuticals To Present At The BIO International Convention On June 17, 2015 6/10/2015 8:04:14 AM
DelMar Pharmaceuticals To Present At The Small-Cap Stars Spring Conference 2015 At Convene In Times Square New York On June 10 6/4/2015 10:20:23 AM
ASCO15 EXCLUSIVE: Experimental Brain Cancer Drugs Heads to Phase II/III Trial This Year: DelMar Pharmaceuticals CEO 6/2/2015 8:04:17 AM
ASCO15: DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data On VAL-083 In Refractory Glioblastoma Multiforme (GBM) At ASCO 6/1/2015 5:04:20 PM
DelMar Pharmaceuticals To Host Investor Conference Call On June 1, 2015 To Discuss New VAL-083 Phase I/II Clinical Data In Patients With Refractory Glioblastoma Multiforme 6/1/2015 11:34:44 AM